Looking at the Narrative for GE HealthCare as Margin Execution and Tech Upside Reshape Expectations

GE HealthCare Technologies stock has seen only a marginal uptick in its fair value estimate to about $89.22 per share, even as the assumed discount rate has eased from roughly 8.40% to around 8.30%. This shift reflects growing confidence in mid term execution rather than a wholesale re rating. At the same time, slightly softer long term revenue growth assumptions near 4.26% suggest analysts are balancing that optimism with caution around macro and market specific risks. As these small but telling shifts accumulate, investors may want to monitor how they can track and interpret future updates to the narrative around this name.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value GE HealthCare Technologies.

🐂 Bullish Takeaways

• BTIG maintains a Buy rating even after trimming its price target to $87 from $89, signaling continued conviction that the stock can outperform as execution stays on track.

• Morgan Stanley, with an Equal Weight rating and a higher target of $80 from $74, cites solid demand, a strong order backlog, and a supportive hospital CapEx environment as underpinnings for steady growth momentum.

• Both firms point to GE HealthCare’s track record and model updates following slightly better than expected Q3 results as evidence that consensus expectations, including about 4% organic revenue growth and adjusted EPS of $4.93 in FY26, look achievable.

• Morgan Stanley also highlights that mid term margin targets appear sensible and sees long term upside risk from photon counting technology, which supports the idea that some structural growth optionality is not fully reflected in the current valuation.

🐻 Bearish Takeaways

• The modest nature of recent target changes, with BTIG cutting its target to $87 and Morgan Stanley only lifting to $80, underscores a view that a meaningful portion of the upside from strong execution, cost discipline, and technology driven growth may already be reflected in the share price.

• With one firm staying at Equal Weight and the other reducing its target despite a Buy rating, there is an implicit caution that while FY26 goals look attainable, investors still face valuation sensitivity and the risk that near term macro or market specific headwinds could cap multiple expansion.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

• GE HealthCare is reportedly exploring strategic options for its China operations, including a possible sale of a minority stake that could value the business at several billion dollars, highlighting potential portfolio reshaping in a critical growth market.

• The company and Mayo Clinic launched the GEMINI RT initiative, a major expansion of their collaboration focused on using AI, multimodal imaging, and connected care to personalize radiation therapy and improve cancer outcomes.

• GE HealthCare unveiled Photonova Spectra, a new photon counting CT platform built on Deep Silicon detector technology and NVIDIA accelerated computing, aiming to deliver ultra high definition imaging and richer spectral data for neurology, oncology, and cardiology.

• Reaffirming its 2025 outlook for approximately 3% organic revenue growth, GE HealthCare also completed a 200 million dollar share repurchase program, underscoring both confidence in its medium term trajectory and ongoing commitment to disciplined capital returns.